TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05958615

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reimagining Us in the Context of Bariatric Surgery (ReConnect)
Description: ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Reimagining Us in the Context of Bariatric Surgery (ReConnect)
Description: ReConnect is an intervention for bariatric surgery patients approximately 2 years after surgery and their romantic partners to participate in together with the goal of improving mental health and enhancing resilience. The intervention is entirely remotely-delivered via handouts sent by PDF and mail to participants instructing them through the 8 weekly modules, as well as associated videos. Each module features psychoeducational materials, instructions and guidance on positive psychology activities, choices of activities to complete both individually and as a couple, and additional resources relevant to that week's theme. The themes are: channeling strengths and focusing on the positive, clarifying values and finding meaning, goal setting, intimacy and fostering the relationship, open communication and gratitude, self-care and savoring the moment, fostering relationships and acts of kindness, and maintaining progress long-term.
Study: NCT06151522

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha-Agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: OTHER
Intervention: α-adrenergic receptor agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT06129526

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPAVasc
Description: EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: EPAVasc
Description: EPAVasc: 1,875mg EPA / 125mg DHA / 3.75μg Vitamin D / 12mg tocopherol

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil
Description: Corn Oil
Study: NCT04614727

Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: polymeric nano calcium fluoride containing varnish NANO SEAL
Description: It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: polymeric nano calcium fluoride containing varnish NANO SEAL
Description: It consists of four components Silicone polymer provides excellent adhesion to enamel and dentine, with transparent formula. NANO-fluoroapatite flows into enamel micro cracks \& seals it, penetrating into the dentinal tubules closing them eventually. As for the NANO-calcium fluoride it behaves as a fluoride reservoir, provides gradual and long-term fluoride release. The fourth component Amine fluoride (Olaflur) provides immediate fluoride ion release and accelerates natural remineralization.
Study: NCT05164393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX001
Description: Topical gel treatment for once daily application

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVX001
Description: Topical gel treatment for once daily application

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AVX001
Description: Topical gel treatment for once daily application
Study: NCT06274463

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise therapy including a trunk stabilization exercise program
Description: All patients will undergo 30 sessions of exercise therapy, including a trunk stability exercise program, for 30 minutes per day, 5 days a week for 6 weeks
Study: NCT06112574

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visuomotor force control training
Description: Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Visuomotor force control training
Description: Single-task training involves visuomotor finger force tracking and dual-task has an additional cognitive components including visual distraction and working memory.
Study: NCT06430996

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine
Description: The participants chewing either caffeine Gum (CAF trial, containing 3 mg/kg of caffeine) or Placebo Gum (PL) for 10 minutes. After rested for 15 minutes, the participants underwent tests.
Study: NCT05359172

Intervention type: DRUG
Intervention: Tranexamic acid
Description: preoperative intravenous infusion
Study: NCT04802616

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ismigen
Description: Sublingual tablets containing 7 mg of bacterial lysate from the following bacteria: Staphylococcus aureus, Haemophilus influenzae serotype B, Klebsiella pneumoniae, Klebsiella ozaenae, Neiserria catarrhalis, Streptococcus viridans, Streptococcus pyogenes, Streptococcus pneumoniae (6 strains: TY1/EQ11, TY2/EQ22, TY3/EQ14, TY5/EQ15, TY8/EQ23, TY47/EQ24).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched tablets without any active substance.
Study: NCT05525377

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Better living with non-memory led dementia course
Description: Caregivers online training and educational phenotype-specific programme on how to support people with non-memory-led dementia.
Study: NCT05020509

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: medial branch block
Description: lumbar medial branch block

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: medial branch block
Description: lumbar medial branch block
Study: NCT00003714

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrazoloacridine
Description: IV (by vein) over 3 hours every 3 weeks
Study: NCT05738135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aminophylline group
Description: Patients will receive 4 mg/kg aminophylline diluted in 50 ml normal saline over 30 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: Patients will receive 50 ml normal saline over 30 minutes.
Study: NCT04742101

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S65487 and azacitidine
Description: Treatment cycle of combination of S65487 and azacitidine during 4 weeks. Two administration schedules are set up. S65487 will be administered via intravenous (IV) infusion. Azacitidine will be administered via either subcutaneous (SC) or Intravenous (IV) infusion according to local practices.
Study: NCT05161897

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized Nutrition Therapy
Description: Explained in arm/group description.
Study: NCT04223817

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7.0 T RMI
Description: Single 7.0 Tesla MRI of both hands in the same time
Study: NCT05252897

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic necrosectomy with step up approach
Description: Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, step up approach will be adopted.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic necrosectomy with direct approach
Description: Endoscopic necrosectomy will be performed with a forward-viewing gastroscope into the WON cavity. Debridement of necrotic tissue will be performed with irrigation and/or mechanical removal with endoscopic instruments. For this arm, the direct approach will be adopted.
Study: NCT05930119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: 300 mg HMPL-453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: 300 mg HMPL-453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: 300 mg HMPL-453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMPL-453
Description: 300 mg HMPL-453

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: 20 mg of rabeprazole will be administered by mouth once daily.
Study: NCT04772872

Intervention type: OTHER
Intervention: Assessment by Brazelton neonatal behavior for group A,Band C
Description: * Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams.

Intervention type: OTHER
Intervention: Assessment by Brazelton neonatal behavior for group A,Band C
Description: * Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams.

Intervention type: OTHER
Intervention: Assessment by Brazelton neonatal behavior for group A,Band C
Description: * Neonatal neurobehavior will be measured by Brazelton neonatal behavior assessment scale.~* Neonatal maturity will be represented by the variance of estimated gestational age that determined by new Ballard score.~* Apgar score will be represented by the variance of degree of scores.~* Birth weight will be measured in grams.
Study: NCT06048302

Intervention type: DRUG
Group type: OTHER
Intervention: Obicetrapib
Description: 1 single dose of obicetrapib

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obicetrapib
Description: 1 single dose of obicetrapib
Study: NCT05411718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Given by PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Given by PO
Study: NCT05489341

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging with Follow-Up
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging with Follow-Up
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) with follow-up (≥ 3 years) confirmed cases of indolent PCa or benign tissue as negatives.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.

Intervention type: DIAGNOSTIC_TEST
Intervention: Histopathology and Magnetic Resonance Imaging
Description: Reference standard establishes histologically-confirmed (ISUP ≥ 2) cases of csPCa as positives, and histopathology- (ISUP ≤ 1) or MRI- (PI-RADS ≤ 2) confirmed cases of indolent PCa or benign tissue as negatives.
Study: NCT05672329

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 0.2 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 0.2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 4 L/kg/min, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 4 L/kg/min using OptiFlow system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2 L/kg/min using OptiFlow-Switch system, FiO2 1.0 + continuous jaw thrust
Description: Apnoeic Oxygenation with flow rate 2 L/kg/min using OptiFlow-Switch system by Fisher\&Paykel and an oxygen inspiration concentration FiO2 of 1.0
Study: NCT05691894

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FAPI
Description: Patients will receive a tracer dose of 18F (8-10mCi) labelled FAPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAPI
Description: Patients will receive a tracer dose of 68Ga (2-5mCi) labelled FAPI
Study: NCT05720910

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GERONTE
Description: The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway
Study: NCT05260671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Penpulimab combined with cetuximab
Description: PD-1 antibody combined with EGFR inhibitors, biweekly
Study: NCT04687657

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: umbilical cord blood
Description: During the consolidation chemotherapy stage, the umbilical cord blood transfusion is given twice (interval of 1 month) to support treatment. On the first day after umbilical cord blood transfusion, the proportion of NK cells in peripheral blood is detected. If it is less than 20%, the NK cells sre activated by subcutaneous injection of recombinant human interleukin-2 (rhIL-2) on the second day after infusion.
Study: NCT05514769

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
Description: The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Proximal Gastrectomy Anterior Anastomosis With Pyloroplasty
Description: The location of the anastomosis in the anterior of the gastric stump. Pyloroplasty is added in the procedure
Study: NCT04662567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: compare the postoperative pain 1 hour and \~24h post surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: compare the postoperative pain 1 hour and \~24h post surgery
Study: NCT05572008

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Protein nutrition in paediatric Crohn's disease
Description: All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protein nutrition in paediatric Crohn's disease
Description: All participants (N = 40) will undergo the same study procedures:~Eating behaviour questionnaire(s) completion Duration: 5 minutes Frequency 2 Dietary intake data via online computerised recall Duration: 60 minutes Frequency: 3 Collection of blood sample via venepuncture Duration: 15 minutes Frequency 1 Strength Tests Duration: 30 minutes Frequency: 1~Half the participants (N = 20) will return for two more visits and will undergo the following procedures:~MRI Scan Duration: 30 minutes Frequency: 1 Consumption of intrinsically labelled protein Duration: 15 minutes Frequency: 1 Insertion of cannulae into hand Duration: 15 minutes Frequency: 1 Collection of blood sample via cannulae (for protein digestion and inflammatory markers and study endpoints outlined below) Duration: 1 minute Frequency: 17
Study: NCT05917912

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline Hydrochloride
Description: hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline Hydrochloride
Description: hydrogel bottle of ATX01 15% , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: hydrogel bottle of placebo , 0,5ml (1pump) per hand, 1ml (2 pumps) per feet during 3 weeks
Study: NCT06275555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bivalirudin
Description: bivalirudin as an anticoagulant

Intervention type: DRUG
Group type: OTHER
Intervention: unfractionated heparin
Description: unfractionated heparin as an anticoagulant
Study: NCT06093906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Processes and Transition to Health
Description: See arm/group description for details regarding this intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Muscle Relaxation
Description: See arm/group description for details regarding this intervention
Study: NCT05480683

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT exam
Description: Noncontrast CT of the pelvis with specific penile anatomical positioning for coverage and with the protocol optimized for application of Agatston calcium scoring post processing.
Study: NCT06394570

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin
Description: Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
Study: NCT04515875

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Daily Engagement Meaningful Activity (DEMA)
Description: This group will receive 7 individualized sessions, 1 face-to-face session at week 1 and via 6 bi weekly telephone sessions delivered by a trained intervener. DEMA will use the principles of problem-solving therapy and consistent with the overall goals of this intervention; and will provide autonomy support, classify needs and goals, generalize manageable solutions, engage in self-selected activities under family support, and self-evaluate failure and success or renew problem-solving as needed. Each session consists: 1) MCI dyads are guided to use the principles of problem-solving therapy to review their personalized, self-selected meaningful activities and plan next steps to continue the activity, identify and establish a plan for additional activities; and 2) the intervener and dyad discuss one of the 6 topics in the Toolkit such as introducing of the intervention and meaningful activity concepts, understanding MCI, its treatments, management, resources, and planning for the future.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information Support (IS)
Description: This group will attend 1 face-to-face meetings to receive an overview of what will happen in the study and an initial Alzheimer disease educational brochure from the Alzheimer's Association (AA). The face-to-face sessions will take place at the IADC Clinical Core clinic, Indiana University Center of Excellence of Women's Health clinic, or Indiana School of Nursing conference room that based on patient-caregiver dyad's preference. Then they will receive 6 bi weekly follow-up phone calls and have the opportunity to ask only questions related to the educational materials. After completing Time 4 data collection, the patient-caregiver dyads will receive DEMA Self-Management Tool kit package through mail.
Study: NCT03301558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose sodium bicarbonate
Description: 1500 mg sodium bicarbonate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose sodium bicarbonate
Description: 3000 mg sodium bicarbonate
Study: NCT06288555

Intervention type: DIAGNOSTIC_TEST
Intervention: Ipswich touch test
Description: Ipswich touch test: A simple test to screen for diabetic peripheral neuropathy (DPN) by lightly touching the patient's toes with the index finger and asking them to identify which foot is touched.~10g monofilament test: A more sensitive test to confirm DPN by applying a thin nylon fiber to different sites on the patient's feet and asking them to indicate when they feel the pressure.~Test procedure: The patient closes their eyes and the examiner performs both tests in a specific sequence and records the results. The tests are done on healthy skin and not on wounds or calluses.